API is rapidly advancing the application of proteomics to Dx, RxDx, Rx development, and personalized medicine. API finds more molecular features per sample, processes more samples per unit time, and delivers superior data with high reproducibility. These strengths translate into smaller, more economical protein biomarker studies, more studies accomplished per unit resource, improved sensitivity and specificity, and a greater chance of technical and commercial diagnostic success.

Currently, API is developing several internal programs while actively exploring partnership and collaboration opportunities with leading pharmaceutical, diagnostic and tools companies.

If you are interested in collaborating with API, please contact us at .